ICO L'HOSPITALET HOSPITAL DURAN I REYNALS

Research site

Spain Avinguda de la Granvia de l'hospitalet 199-203, 08908 Barcelona, Spain

8 trials recruiting
Colorectal cancer metastatic · Plasma cell myeloma · Lung neoplasm malignant
Adult patients

About Specializations

ICO L'HOSPITALET HOSPITAL DURAN I REYNALS in Barcelona, Spain specialises in clinical trials of conditions such as Colorectal cancer metastatic, Plasma cell myeloma, Lung neoplasm malignant, Small cell lung cancer, and other specialisations. This site conducts important research.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location

Avinguda de la Granvia de l'hospitalet 199-20308908 BarcelonaSpain

Open in maps ↗

Recruiting now: 8 trials
Conditions studied: 21

More sites in Barcelona Spain

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Quick filters

18 clinical trials

Colorectal cancer metastatic

Recruiting

Study of precemtabart tocentecan alone or in drug combination versus standard therapy in previously treated metastatic colorectal cancer patients

Registered drugNo placebo

Study of precemtabart tocentecan alone or in drug combination versus standard therapy in previously treated metastatic colorectal cancer patients

Registered drugNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Bevacizumab
Sponsor:Merck Healthcare KGaA

Contact Research Centre

Lung neoplasm malignant+2

Recruiting

A study to evaluate the effectiveness of tarlatamab in patients with extensive-stage small cell lung cancer that has progressed after prior treatment and who have limited health status

InvestigationalNo placebo

A study to evaluate the effectiveness of tarlatamab in patients with extensive-stage small cell lung cancer that has progressed after prior treatment and who have limited health status

InvestigationalNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Tarlatamab
Sponsor:ETOP IBCSG Partners Foundation

Contact Research Centre

Hepatocellular carcinoma

Recruiting

A Study of Atezolizumab and Bevacizumab Before and After Surgery in Patients with Liver Cancer at High Risk of Coming Back

Registered drugNo placebo

A Study of Atezolizumab and Bevacizumab Before and After Surgery in Patients with Liver Cancer at High Risk of Coming Back

Registered drugNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Atezolizumab
Sponsor:Fundacio De Recerca Clinic Barcelona-Institut D’investigacions Biomediques August Pi I Sunyer

Contact Research Centre

Mantle cell lymphoma

Recruiting

Study on the Effectiveness and Safety of Pirtobrutinib and Rituximab for Untreated Adult Patients with Indolent Mantle Cell Lymphoma

Registered drugNo placebo

Study on the Effectiveness and Safety of Pirtobrutinib and Rituximab for Untreated Adult Patients with Indolent Mantle Cell Lymphoma

Registered drugNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Pirtobrutinib
Sponsor:Fundacion Geltamo

Contact Research Centre

Colorectal cancer metastatic

Recruiting

Study on Cetuximab and Drug Combination for Patients with Metastatic Colorectal Cancer

Registered drugNo placebo

Study on Cetuximab and Drug Combination for Patients with Metastatic Colorectal Cancer

Registered drugNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Bevacizumab
Sponsor:Gruppo Oncologico Dell'Italia Meridionale

Contact Research Centre

Chronic lymphocytic leukaemia+1

Recruiting

Study on Zanubrutinib and Obinutuzumab for Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Patients

Registered drugNo placebo

Study on Zanubrutinib and Obinutuzumab for Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Patients

Registered drugNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Obinutuzumab
Sponsor:Fundacion PETHEMA

Contact Research Centre

Metastatic renal cell carcinoma

Recruiting

Study of Axitinib and Nivolumab for Patients with Metastatic Renal Cell Carcinoma Not Responding Completely to Initial Treatment

Registered drugNo placebo

Study of Axitinib and Nivolumab for Patients with Metastatic Renal Cell Carcinoma Not Responding Completely to Initial Treatment

Registered drugNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Axitinib
Sponsor:Consorzio Oncotech

Contact Research Centre

Breast cancer+2

Recruiting

Study on Pembrolizumab and Paclitaxel for Early Triple-Negative Breast Cancer in Patients with High Tumor-Infiltrating Lymphocytes

Registered drugNo placebo

Study on Pembrolizumab and Paclitaxel for Early Triple-Negative Breast Cancer in Patients with High Tumor-Infiltrating Lymphocytes

Registered drugNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Paclitaxel
Sponsor:Institut Gustave Roussy

Contact Research Centre

Squamous cell carcinoma of skin

Not yet recruiting

A study of cemiplimab in patients with locally advanced cutaneous squamous cell carcinoma

Registered drugNo placebo

A study of cemiplimab in patients with locally advanced cutaneous squamous cell carcinoma

Registered drugNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Cemiplimab
Sponsor:Fundacio Institut D'Investigacio Biomedica De Bellvitge IDIBELL

Contact Research Centre

Acute myeloid leukaemia

Not recruiting

Pharmacokinetic, Safety, and Efficacy Evaluation of ASTX727 and Venetoclax in Adult Patients with Acute Myeloid Leukemia

Registered drugNo placebo

Pharmacokinetic, Safety, and Efficacy Evaluation of ASTX727 and Venetoclax in Adult Patients with Acute Myeloid Leukemia

Registered drugNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Cedazuridine
Sponsor:Taiho Oncology Inc.

Contact Research Centre

Glioblastoma

Not recruiting

Study on the Effectiveness of Optune with Temozolomide and Pembrolizumab in Patients with Newly Diagnosed Glioblastoma

Registered drug

Study on the Effectiveness of Optune with Temozolomide and Pembrolizumab in Patients with Newly Diagnosed Glioblastoma

Registered drug

Spain

Participants:18–64 years · 65+ years
Substances:Pembrolizumab
Sponsor:Novocure GmbH

Contact Research Centre

Neuroendocrine carcinoma

Not recruiting

Study on Enfortumab Vedotin for Patients with Advanced Neuroendocrine Carcinoma Not Responding to or Ineligible for Platinum Chemotherapy

Registered drugNo placebo

Study on Enfortumab Vedotin for Patients with Advanced Neuroendocrine Carcinoma Not Responding to or Ineligible for Platinum Chemotherapy

Registered drugNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Enfortumab Vedotin
Sponsor:Grupo Espanol De Tumores Neuroendocrinos

Contact Research Centre

Is this your site?

Join our network of research sites

Get verified: confirm your contact details and recruitment status with us, appear first on the pages of your trials and receive patient requests directly.

See the offer for sites